A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) have become a critical regimen for tumor therapy, but the efficacy of monotherapy is usually limited by drug resistance and multiple angiogenic mechanisms. Complement proteins are becoming potential candidates for cancer-targ...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Oncolytics
Main Authors: Wang, Huiling, Li, Yiming, Shi, Gang, Wang, Yuan, Lin, Yi, Wang, Qin, Zhang, Yujing, Yang, Qianmei, Dai, Lei, Cheng, Lin, Su, Xiaolan, Yang, Yang, Zhang, Shuang, Li, Zhi, Li, Jia, Wei, Yuquan, Yu, Dechao, Deng, Hongxin
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Gene & Cell Therapy 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940616/
https://ncbi.nlm.nih.gov/pubmed/31909182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2019.12.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares